ES2758659T3 - Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa - Google Patents
Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa Download PDFInfo
- Publication number
- ES2758659T3 ES2758659T3 ES12806720T ES12806720T ES2758659T3 ES 2758659 T3 ES2758659 T3 ES 2758659T3 ES 12806720 T ES12806720 T ES 12806720T ES 12806720 T ES12806720 T ES 12806720T ES 2758659 T3 ES2758659 T3 ES 2758659T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- formula
- product
- hours
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AEDVAGWYAKIOIM-UHFFFAOYSA-N COc1cc(C(O)=O)cc([N+]([O-])=O)c1O Chemical compound COc1cc(C(O)=O)cc([N+]([O-])=O)c1O AEDVAGWYAKIOIM-UHFFFAOYSA-N 0.000 description 1
- ASOADIZOVZTJSR-UHFFFAOYSA-N Cc(c(Cl)c1C)c(-c2n[o]c(-c(cc3O)cc([N+]([O-])=O)c3O)n2)c(Cl)[n+]1[O-] Chemical compound Cc(c(Cl)c1C)c(-c2n[o]c(-c(cc3O)cc([N+]([O-])=O)c3O)n2)c(Cl)[n+]1[O-] ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 description 1
- NIEYLRZZLYWRNJ-UHFFFAOYSA-N Cc1c(-c2n[o]c(-c3cc(O)cc(N)c3)n2)c(Cl)[n-]c(C)c1Cl Chemical compound Cc1c(-c2n[o]c(-c3cc(O)cc(N)c3)n2)c(Cl)[n-]c(C)c1Cl NIEYLRZZLYWRNJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570141P | 2011-12-13 | 2011-12-13 | |
| GBGB1121413.7A GB201121413D0 (en) | 2011-12-13 | 2011-12-13 | Chemical compounds and processes |
| US201261593625P | 2012-02-01 | 2012-02-01 | |
| GBGB1201758.8A GB201201758D0 (en) | 2012-02-01 | 2012-02-01 | Chemical compounds and processes |
| US201261718589P | 2012-10-25 | 2012-10-25 | |
| PCT/PT2012/000048 WO2013089573A1 (en) | 2011-12-13 | 2012-12-12 | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2758659T3 true ES2758659T3 (es) | 2020-05-06 |
Family
ID=48612903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12806720T Active ES2758659T3 (es) | 2011-12-13 | 2012-12-12 | Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa |
| ES19194756T Active ES2960805T3 (es) | 2011-12-13 | 2012-12-12 | Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19194756T Active ES2960805T3 (es) | 2011-12-13 | 2012-12-12 | Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9126988B2 (https=) |
| EP (2) | EP2791134B1 (https=) |
| JP (3) | JP6456143B2 (https=) |
| BR (1) | BR112014014341A2 (https=) |
| CA (2) | CA3088684C (https=) |
| CY (1) | CY1122580T1 (https=) |
| DK (1) | DK2791134T3 (https=) |
| ES (2) | ES2758659T3 (https=) |
| HR (1) | HRP20192133T8 (https=) |
| HU (1) | HUE047856T2 (https=) |
| PL (1) | PL2791134T3 (https=) |
| PT (2) | PT2791134T (https=) |
| RS (1) | RS59666B1 (https=) |
| SI (1) | SI2791134T1 (https=) |
| WO (1) | WO2013089573A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| WO2009116882A1 (en) | 2008-03-17 | 2009-09-24 | Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| JP6456143B2 (ja) * | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| GB2563858A (en) * | 2017-06-27 | 2019-01-02 | Azad Pharmaceutical Ingredients Ag | New route of synthesis for opicapone |
| US20210087183A1 (en) * | 2017-12-18 | 2021-03-25 | Unichem Laboratories Ltd | Process for the preparation of opicapone and intermediates thereof |
| EP3860602A1 (en) * | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| CN109529881A (zh) * | 2018-11-12 | 2019-03-29 | 刘晓菊 | 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法 |
| WO2021182981A1 (en) | 2020-03-13 | 2021-09-16 | BIAL - PORTELA & Cª, S.A. | Micronised opicapone |
| TW202200138A (zh) * | 2020-05-26 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 包含奧匹卡朋（ｏｐｉｃａｐｏｎｅ）之錠劑 |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| EP4262798A1 (en) | 2020-12-17 | 2023-10-25 | Bial-Portela & CA, S.A. | Treatment regimens for early idiopathic parkinson's disease |
| CN112375014A (zh) * | 2020-12-17 | 2021-02-19 | 重庆柳江医药科技有限公司 | 一种奥匹卡朋工艺杂质及制备方法和用途 |
| US20240300930A1 (en) * | 2021-02-26 | 2024-09-12 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
| GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| GB202219669D0 (en) | 2022-12-23 | 2023-02-08 | Bial Portela & Ca Sa | Processes and intermediates for synthesising opicapone |
| EP4719374A1 (en) | 2023-05-25 | 2026-04-08 | Bial-Portela & CA, S.A. | Treatment regimens for early idiopathic parkinson's disease |
| EP4727649A1 (en) * | 2023-06-19 | 2026-04-22 | Medichem, S.A. | Process for preparing opicapone |
| AU2024288001A1 (en) | 2023-07-11 | 2026-01-15 | Tay Therapeutics Limited | Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents |
| CN119775271A (zh) * | 2024-12-31 | 2025-04-08 | 南京海纳医药科技股份有限公司 | 一种奥吡卡朋粗品的精制方法 |
| CN120081837A (zh) * | 2025-02-14 | 2025-06-03 | 江苏天士力帝益药业有限公司 | 一种低单杂高纯度的奥匹卡朋中间体05的制备方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| ES2066092T3 (es) | 1990-11-29 | 1995-03-01 | Wei Ming Pharmaceutical Mfg Co | Coadyuvante para la formacion directa de comprimidos. |
| EP0619814A1 (en) | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| FR2730322B1 (fr) | 1995-02-02 | 1997-04-30 | Imago | Monture de lunettes metallique |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| KR100875222B1 (ko) | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| JP2004532611A (ja) | 2000-11-28 | 2004-10-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１９ |
| WO2002051442A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| MXPA03007513A (es) | 2001-02-21 | 2004-07-30 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. |
| WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| JP2005504014A (ja) | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法 |
| PT1408964E (pt) | 2001-07-26 | 2007-05-31 | Merck Patent Gmbh | Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis. |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| CN100364531C (zh) | 2002-12-18 | 2008-01-30 | 西托维亚公司 | 3,5－二取代－[1,2,4]－二唑及类似物和其用途 |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| WO2005013982A1 (en) | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| WO2006071184A1 (en) | 2004-12-28 | 2006-07-06 | Astrazeneca Ab | Aryl sulphonamide modulators |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| US8017631B2 (en) | 2005-04-26 | 2011-09-13 | Neurosearch A/S | Oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1954137A4 (en) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| WO2007063946A1 (ja) | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| KR101669432B1 (ko) | 2007-08-27 | 2016-10-26 | 다트 뉴로사이언스 (케이만) 엘티디. | 치료적 이속사졸 화합물 |
| MX2010009043A (es) | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
| WO2009116882A1 (en) * | 2008-03-17 | 2009-09-24 | Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| ES2723729T3 (es) | 2008-07-29 | 2019-08-30 | Bial Portela & Ca Sa | Régimen de administración de nitrocatecoles |
| BRPI1016132B8 (pt) | 2009-04-01 | 2021-05-25 | Bial Portela & Ca Sa | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| EA026419B1 (ru) | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| JP6456143B2 (ja) * | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
-
2012
- 2012-12-12 JP JP2014547135A patent/JP6456143B2/ja active Active
- 2012-12-12 CA CA3088684A patent/CA3088684C/en active Active
- 2012-12-12 HR HRP20192133TT patent/HRP20192133T8/hr unknown
- 2012-12-12 WO PCT/PT2012/000048 patent/WO2013089573A1/en not_active Ceased
- 2012-12-12 PT PT128067204T patent/PT2791134T/pt unknown
- 2012-12-12 PL PL12806720T patent/PL2791134T3/pl unknown
- 2012-12-12 RS RS20191562A patent/RS59666B1/sr unknown
- 2012-12-12 CA CA2858025A patent/CA2858025C/en active Active
- 2012-12-12 ES ES12806720T patent/ES2758659T3/es active Active
- 2012-12-12 US US14/365,265 patent/US9126988B2/en active Active
- 2012-12-12 EP EP12806720.4A patent/EP2791134B1/en active Active
- 2012-12-12 PT PT191947563T patent/PT3604299T/pt unknown
- 2012-12-12 ES ES19194756T patent/ES2960805T3/es active Active
- 2012-12-12 SI SI201231703T patent/SI2791134T1/sl unknown
- 2012-12-12 DK DK12806720T patent/DK2791134T3/da active
- 2012-12-12 HU HUE12806720A patent/HUE047856T2/hu unknown
- 2012-12-12 EP EP19194756.3A patent/EP3604299B1/en active Active
- 2012-12-12 BR BR112014014341A patent/BR112014014341A2/pt not_active Application Discontinuation
-
2015
- 2015-07-31 US US14/814,603 patent/US9630955B2/en active Active
-
2017
- 2017-10-27 JP JP2017207738A patent/JP6721558B2/ja active Active
-
2019
- 2019-11-27 JP JP2019214566A patent/JP2020059729A/ja not_active Withdrawn
- 2019-11-27 CY CY20191101241T patent/CY1122580T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20192133T8 (hr) | 2021-02-19 |
| US20160009700A1 (en) | 2016-01-14 |
| US20140350057A1 (en) | 2014-11-27 |
| JP6456143B2 (ja) | 2019-01-23 |
| CA2858025C (en) | 2020-09-22 |
| WO2013089573A1 (en) | 2013-06-20 |
| US9630955B2 (en) | 2017-04-25 |
| SI2791134T1 (sl) | 2020-01-31 |
| JP2015500335A (ja) | 2015-01-05 |
| ES2960805T3 (es) | 2024-03-06 |
| DK2791134T3 (da) | 2019-12-09 |
| EP3604299A1 (en) | 2020-02-05 |
| BR112014014341A2 (pt) | 2017-08-22 |
| EP2791134A1 (en) | 2014-10-22 |
| US9126988B2 (en) | 2015-09-08 |
| PT3604299T (pt) | 2023-10-31 |
| CA2858025A1 (en) | 2013-06-20 |
| RS59666B1 (sr) | 2020-01-31 |
| CA3088684C (en) | 2021-10-26 |
| EP2791134B1 (en) | 2019-09-25 |
| EP3604299B1 (en) | 2023-07-26 |
| HRP20192133T1 (hr) | 2020-02-21 |
| JP2018052949A (ja) | 2018-04-05 |
| CY1122580T1 (el) | 2021-01-27 |
| HUE047856T2 (hu) | 2020-05-28 |
| JP6721558B2 (ja) | 2020-07-15 |
| PT2791134T (pt) | 2019-12-18 |
| PL2791134T3 (pl) | 2020-03-31 |
| JP2020059729A (ja) | 2020-04-16 |
| CA3088684A1 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2758659T3 (es) | Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa | |
| PT2059513E (pt) | Processo para a preparação de ácidos 1,2,4-oxadiazolebenzóicos | |
| ES2355729T3 (es) | Nuevos polimorfos cristalinos del clopidogrel. | |
| JP4917440B2 (ja) | Ｇａｂａａアゴニストの多形性形態 | |
| JP2006516653A (ja) | キナーゼ阻害剤ピロロトリアジンの製造方法 | |
| ES2362660T3 (es) | Cristalización de formas sólidas de sales de adición de clopidogrel. | |
| AU2021277593A1 (en) | Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate | |
| CN100999522B (zh) | 巴马汀的制备方法 | |
| CN117964617A (zh) | 一种GLP-1受体激动剂Orforglipron的制备方法 | |
| JP5523095B2 (ja) | 修飾マクロファージ遊走阻止因子阻害剤 | |
| CN115160321B (zh) | 一种伐地那非类似物及其合成方法和应用 | |
| TWI909320B (zh) | 抗病毒性1,3-二氧代茚化合物 | |
| JP2009530404A5 (https=) | ||
| ES2303462B1 (es) | Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura. | |
| EP3097097A1 (en) | Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection | |
| CA3048771C (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
| WO2024069492A1 (en) | Processes for the preparation and manufacture of relugolix | |
| GGL | pharmacokinetie or pharmacodynamic properties, or to clinical efficiency or safety. | |
| HK1206980A1 (en) | Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation | |
| CN102531999A (zh) | 无定形盐酸乐卡地平及其制备方法 |